Leveraging drug target Mendelian randomization to predict the effect of lipoprotein(a) inhibition

利用药物靶标孟德尔随机化来预测脂蛋白(a) 抑制的效果

• 批准号: 473838
• 负责人: Legault Marc-Andre
• 金额: $ 9.83万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-10-01 至 2025-10-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=473838&lang=en
• 关键词: Cardiovascular Disease; Drug Targets; Genetics; Lipoprotein(A); Machine Learning; Mendelian Randomization

Drugs exert their effects through the product of genes encoded in our DNA. Genetic variation in these genes often have similar effects as the corresponding drugs and represent a rich source of data to develop new drugs or to better understand health impac

药物通过我们DNA中编码的基因产物发挥作用。这些基因的遗传变异通常与相应的药物具有相似的作用，并为开发新药或更好地了解健康影响提供了丰富的数据来源。